SUSD2

Across TCGA pan-cancer cohorts, SUSD2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SUSD2 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher SUSD2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SUSD2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

THCA, LIHC, and LUAD are the cancer types where SUSD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	DFS	Median	All	0.061	0.841	<.001	6	view →
LIHC	DFS	Median	II,III,IV	0.092	0.429	.014	6	view →
LUAD	DFS	Median	All	0.300	0.680	.008	6	view →
LGG	DFS	Median	All	0.110	0.826	<.001	3	view →
SKCM	DFS	Median	II,III,IV	0.853	0.675	.014	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SUSD2–THCA (DFS)

Open the THCA breakdown →